Health and Fitness Health and Fitness
Wed, August 18, 2010
Tue, August 17, 2010
Mon, August 16, 2010
Fri, August 13, 2010
Thu, August 12, 2010
Wed, August 11, 2010
Tue, August 10, 2010
Mon, August 9, 2010
Fri, August 6, 2010
Thu, August 5, 2010
Wed, August 4, 2010
Tue, August 3, 2010
Mon, August 2, 2010
Fri, July 30, 2010
Thu, July 29, 2010
Wed, July 28, 2010
Tue, July 27, 2010

Exelixis Announces August 12 Webcast of Presentation at the Canaccord Genuity 30th Annual Growth Conference


//health-fitness.news-articles.net/content/2010/ .. ccord-genuity-30th-annual-growth-conference.html
Published in Health and Fitness on Friday, August 6th 2010 at 4:27 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the companya™s vice president of investor relations and corporate communications, will present at the Canaccord Genuity 30th Annual Growth Conference at 10:30 a.m. EDT / 7:30 a.m. PDT on Thursday, August 12, 2010 in Boston. Mr. Butler will discuss the companya™s corporate strategy, development pipeline and financial outlook, and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors and Media at [ http://www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixisa™ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the companya™s web site at [ http://www.exelixis.com ].

Exelixis and the Exelixis logo are registered U.S. trademarks.


Publication Contributing Sources